Industry’s historic lack of follow through on post-market studies for expedited pathways could hinder the FDA's willingness to push the limits of the EUA pathway. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
